Traders should monitor for potential near-term dilution impact; however, the capital raise strengthens Spyre’s cash position for clinical development. The stock may react negatively short-term due to dilution, but long-term impact depends on pipeline execution.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $68.99entry
- T+1 · 7mo ago +1.03%α +0.78% · $69.70
- T+5 · 7mo ago +5.81%α +4.17% · $73.00
- T+20 · 6mo ago +8.77%α +2.73% · $75.04
- T+60 · 4mo ago +41.67%α +33.54% · $97.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, raising approximately $403.0 million in gross proceeds, with an additional $60.5 million option for underwriters to purchase more shares. The offering is expected to close on April 16, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Spyre Therapeutics is offering 6,500,000 shares of common stock at $62.00 per share.
- Gross proceeds are expected to be approximately $403.0 million, before underwriting discounts and expenses.
- Underwriters have a 30-day option to purchase up to an additional $60.5 million worth of shares.
- The offering is expected to close on or about April 16, 2026.
- Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities are joint book-running managers.
Financial Impact
$403.0 million raised, with potential for $463.5 million total if the overallotment is exercised
Risk Factors
- Dilution to existing shareholders from the issuance of new shares
- Market conditions and investor sentiment toward biotech offerings may affect pricing and demand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274098 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers